Anavex Life Sciences Corp.

LSE:0HFR Stock Report

Market Cap: US$910.9m

Anavex Life Sciences Management

Management criteria checks 3/4

Anavex Life Sciences' CEO is Chris Missling, appointed in Jul 2013, has a tenure of 11.5 years. total yearly compensation is $2.78M, comprised of 25.1% salary and 74.9% bonuses, including company stock and options. directly owns 1.47% of the company’s shares, worth $13.43M. The average tenure of the management team and the board of directors is 3 years and 10.7 years respectively.

Key information

Chris Missling

Chief executive officer

US$2.8m

Total compensation

CEO salary percentage25.1%
CEO tenure11.5yrs
CEO ownership1.5%
Management average tenure3yrs
Board average tenure10.7yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Chris Missling's remuneration changed compared to Anavex Life Sciences's earnings?
DateTotal CompensationSalaryCompany Earnings
Sep 30 2024US$3mUS$700k

-US$43m

Jun 30 2024n/an/a

-US$42m

Mar 31 2024n/an/a

-US$41m

Dec 31 2023n/an/a

-US$43m

Sep 30 2023US$4mUS$700k

-US$48m

Jun 30 2023n/an/a

-US$52m

Mar 31 2023n/an/a

-US$53m

Dec 31 2022n/an/a

-US$50m

Sep 30 2022US$7mUS$586k

-US$48m

Jun 30 2022n/an/a

-US$45m

Mar 31 2022n/an/a

-US$43m

Dec 31 2021n/an/a

-US$41m

Sep 30 2021US$9mUS$550k

-US$38m

Jun 30 2021n/an/a

-US$32m

Mar 31 2021n/an/a

-US$28m

Dec 31 2020n/an/a

-US$28m

Sep 30 2020US$2mUS$550k

-US$26m

Jun 30 2020n/an/a

-US$26m

Mar 31 2020n/an/a

-US$26m

Dec 31 2019n/an/a

-US$26m

Sep 30 2019US$3mUS$513k

-US$26m

Jun 30 2019n/an/a

-US$26m

Mar 31 2019n/an/a

-US$23m

Dec 31 2018n/an/a

-US$20m

Sep 30 2018US$3mUS$500k

-US$17m

Compensation vs Market: Chris's total compensation ($USD2.78M) is above average for companies of similar size in the UK market ($USD1.49M).

Compensation vs Earnings: Chris's compensation has been consistent with company performance over the past year.

CEO

Chris Missling (58 yo)

11.5yrs

Tenure

US$2,783,700

Compensation

Dr. Christopher U. Missling, also known as the Chris, MS, Ph D., MBA, has been the Chief Executive Officer and President at Anavex Life Sciences Corp. since July 05, 2013 and also serves as its Director an...

Leadership Team

NamePositionTenureCompensationOwnership
Christopher Missling
President11.5yrsUS$2.78m1.47%
$ 13.4m
Sandra Boenisch
Principal Financial Officer & Treasurer9.3yrsUS$402.23k0.027%
$ 246.6k
Walter Kaufmann
Chief Scientific Officer3yrsno datano data
Clint Tomlinson
VP of Corporateno datano datano data
Adebayo Laniyonu
Senior Vice President of Nonclinical Development3.7yrsno datano data
Edward Hammond
Chief Medical Officer3yrsno datano data
Kun Jin
Head of Biostatistics1.8yrsno datano data
David Goldberger
Senior Vice President of Regulatory Affairs1.2yrsno datano data
Terrie Kellmeyer
Senior Vice President of Clinical Developmentless than a yearno datano data
Juan Carlos Lopez-Talavera
Senior VP & Head of Research and Developmentless than a yearno datano data

3.0yrs

Average Tenure

Experienced Management: 0HFR's management team is considered experienced (3 years average tenure).

Board Members

NamePositionTenureCompensationOwnership
Christopher Missling
President11.5yrsUS$2.78m1.47%
$ 13.4m
Jiong Ma
Independent Chairman3.7yrsUS$243.20kno data
Jacqueline A. French
Member of the Scientific Advisory Board9.8yrsno datano data
Paul Aisen
Member of the Scientific Advisory Board13.9yrsno datano data
John Harrison
Member of the Scientific Advisory Board11.1yrsno datano data
Ottavio Arancio
Member of the Scientific Advisory Board11.2yrsno datano data
Tangui Maurice
Member of the Scientific Advisory Boardno datano datano data
Athanasios Skarpelos
Independent Director12yrsUS$227.20k1.54%
$ 14.0m
Norman Relkin
Member of the Scientific Advisory Board10.7yrsno datano data
Corinne Lasmézas
Member of the Scientific Advisory Board9.8yrsno datano data
Steffen Thomas
Independent Director9.6yrsUS$227.20k0.0059%
$ 53.7k
Claus van der Velden
Lead Independent Director6.8yrsUS$243.20kno data

10.7yrs

Average Tenure

58yo

Average Age

Experienced Board: 0HFR's board of directors are seasoned and experienced ( 10.7 years average tenure).

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/01/01 15:58
End of Day Share Price 2024/12/31 00:00
Earnings2024/09/30
Annual Earnings2024/09/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

Anavex Life Sciences Corp. is covered by 14 analysts. 3 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Caroline PalomequeBerenberg
Yun ZhongBTIG
Charles DuncanCantor Fitzgerald & Co.